The Arkansas Supreme Court tossed out a $1.2 billion judgment against Johnson & Johnson, reversing a lower court verdict that found the company engaged in fraudulent tactics when marketing the antipsychotic drug Risperdal. The high court ruled the state's Medicaid fraud law regulates health care facilities and that drug manufacturers don't fall under its scope. Read the full story